Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Viral Vector Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...
The "Viral Vector Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Viral Vector Collaboration and Licensing Deals provides a comprehensive ...
The field of cell and gene therapy (CGT) has made remarkable strides in recent years, offering new hope to patients across an increasingly wide range of conditions. However, the field’s growth has ...
From rare diseases to common chronic conditions, advances in viral vector-based gene therapies are bringing exciting new clinical possibilities to the table. But current costs per dose land as high as ...
Viral vectors are a key component of many advanced gene therapies and vaccines, but reliable, large-scale manufacturing remains a significant challenge. Continued innovation in vector design, cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results